Reconsidering the Trade-offs of Prostate Cancer Screening

Shoag and colleagues review the long-term results of PSA screening from randomized trials and raise questions about whether the risk–benefit ratio is as strongly in favor of risk over benefit as currently gauged. The decline in PSA screening appears to have been precipitated in part by misinterpreta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-06, Vol.382 (25), p.2465-2468
Hauptverfasser:	Shoag, Jonathan E, Nyame, Yaw A, Gulati, Roman, Etzioni, Ruth, Hu, Jim C
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Biopsy Breast cancer Cancer screening Clinical decision making Clinical trials Decision making Early Detection of Cancer Erectile dysfunction Follow-Up Studies Humans Magnetic resonance imaging Male Medical diagnosis Medical screening Men Metastasis Mortality Patients Postoperative Complications Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - diagnosis Prostatic Neoplasms - mortality Prostatic Neoplasms - surgery Quality of life Radiation therapy Randomized Controlled Trials as Topic Short term Urinary incontinence Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Shoag and colleagues review the long-term results of PSA screening from randomized trials and raise questions about whether the risk–benefit ratio is as strongly in favor of risk over benefit as currently gauged. The decline in PSA screening appears to have been precipitated in part by misinterpretations of data from randomized trials.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMsb2000250